logo

For the Inventor, By the Inventor

Seongnam, South Korea

Kyung Ah Kim

This inventor holds 24 USPTO granted patents and 3 published patent applications and 6 EPO patents, primarily in Cancer Therapy. Top assignees: Samsung Electronics Co., Ltd., Dongjin Semichem Co., Ltd., Georgetown University. Active years: 2011-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kyung Ah Kim. Retrieved from https://idiyas.com/inventor/kyung-ah-kim

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 

% Patents Active = 95.8


Average Co-Inventor Count = 3.9

ph-index = 3

Forward Citations = 45(Granted Patents)


Location History:

  • Hwaseong-Si, KR (2011)
  • Seoul, KR (2016)
  • Seongnam-si, KR (2015 - 2020)

Company Filing History:

goldMedal24 out of 132,108 
 
Samsung Electronics Co., Ltd.
 patents
silverMedal1 out of 107 
 
Dongjin Semichem Co., Ltd.
 patents
bronzeMedal1 out of 499 
 
Georgetown University
 patents
4. 1 out of 145 
 
Samsung Life Public Welfare Foundation
 patents
5. 1 out of 8 
 
Samsung Life Welfare Foundation
 patents
6. 1 out of 1,486 
 
Yonsei University
 patents
where one patent can have more than one assignee

Years Active: 2011-2020

Loading Chart...
Loading Chart...
Areas of Expertise:
Biomarker PNCK
c-Met Inhibitor
Combination Therapy
Hsp90 Biomarker
Anti-c-Met Antibody
EGFR Antagonist
PDGF Biomarker
Beta-Catenin Inhibitor
FGFR Inhibitor
VEGF-Binding Fragment
Dual Inhibitor
Solid Cancers
24 patents (USPTO):Explore Patents
1. 10578621 - Biomarker PNCK for predicting effect of a dual-targeting agent (2020-03-03),
2. 10472682 - Prediction of effect of a c-Met inhibitor using mutation of KRAS or BRAF (2019-11-12),
3. 10188647 - Combination therapy using P53 activator and c-Met inhibitor (2019-01-29),
4. 10064939 - Combination therapy using c-Met inhibitor and IGF-1R inhibitor for c-Met inhibitor resistant cancers (2018-09-04),
5. 9956244 - Biomarker Hsp90 for predicting effect of a c-Met inhibitor (2018-05-01),
6. 9943596 - Combination therapy using dual inhibitor of c-MET and EGFR and IGF-1R inhibitor (2018-04-17),
7. 9931400 - Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases (2018-04-03),
8. 9869668 - PDGF as a biomarker for predicting resistance or effect of c-Met targeting drugs (2018-01-16),
9. 9850537 - Biomarker TFF1 for predicting effect of C-MET inhibitor (2017-12-26),
10. 9808507 - Anti-c-Met/anti-Ang2 bispecific antibody (2017-11-07),
11. 9717715 - Method of combination therapy using an anti-C-Met antibody (2017-08-01),
12. 9650443 - Fusion protein comprising anti-c-Met antibody and VEGF-binding fragment (2017-05-16),
13. 9572878 - Method of combination therapy using an EGFR antagonist and anti-c-Met antibody (2017-02-21),
14. 9567641 - Combination therapy for the treatment of cancer using an anti-C-met antibody (2017-02-14),
15. 9556275 - Combination therapy using anti-C-met antibody and anti-ang-2 antibody (2017-01-31),

Title: Kyung Ah Kim: Innovator in Dual-Targeting Cancer Therapies

Introduction

Kyung Ah Kim, based in Seongnam-si, South Korea, is a prolific inventor with a remarkable portfolio of 24 patents. His innovative work primarily focuses on advancements in cancer treatment, particularly through the development of biomarkers and dual-targeting agents.

Latest Patents

Among his latest groundbreaking patents, Kyung Ah Kim has developed a biomarker known as PNCK, which is pivotal for predicting the effect of a dual-targeting agent aimed at both c-Met and EGFR. This patent provides a method for predicting the effectiveness of the dual-targeting agent, as well as for selecting suitable subjects for its application and monitoring the agent's effects through the measurement of PNCK levels or its coding gene. Additionally, he has patented a method for predicting and monitoring the efficacy of a c-Met inhibitor by utilizing mutations in KRAS or BRAF, offering a pathway for selecting appropriate subjects for treatment and potentially ameliorating cancer through targeted therapy.

Career Highlights

Kyung Ah Kim has contributed significantly to his field during his tenure at renowned companies such as Samsung Electronics Co., Ltd. and the Samsung Life Welfare Foundation. His work has been instrumental in pushing the boundaries of cancer treatment and therapy development.

Collaborations

Throughout his career, he has collaborated with notable colleagues like Ji Min Lee and Bo Gyou Kim. These partnerships have fostered an environment of innovation, resulting in the successful development of transformative cancer therapies.

Conclusion

Kyung Ah Kim's contributions to the field of oncology through his inventions and patents exemplify his dedication to improving cancer treatment. His innovative use of biomarkers and dual-targeting agents marks a significant advancement in personalized medicine, showcasing his role as a leading inventor in this crucial area of healthcare.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…